Literature DB >> 24887334

Therapeutic adherence to osteoporosis treatment.

Sona Tomková, Danica Telepková, Peter Vanuga, Zdenko Killinger, Ivana Sulková, Peter Celec, Juraj Payer.   

Abstract

OBJECTIVE: Adherence of patients to therapy is a major determinant of therapeutic success, which is not included in most clinical studies. This is especially true for chronic diseases with few subjective symptoms, such as osteoporosis. The aim of our study was to describe and to analyze the therapeutic adherence to several widely used anti-osteoporotic medications in real-world medicine in Slovakia.
METHODS: Using a retrospective approach, data about drug prescriptions for 8,223 patients from 3 consecutive years were analyzed regarding compliance and persistence. Compliance was measured as medication possession ratio-ratio between the supply of the drugs in the treatment time according to the prescriptions and the time of observation. Persistence was assessed as the percentage of patients who used the drug without a gap for the given time period.
RESULTS: The average compliance was 70%, 59%, and 4% for 6, 12, and 24 months, respectively. Average persistence was very low with 54%, 42%, and 22% for 6, 12, and 24 months, respectively. Total average persistence was only 9.8 months. Medications with lower frequency of application tended to be associated with higher adherence.
CONCLUSION: In conclusion, the therapeutic adherence to anti-osteoporotic treatments varies between the available drugs and drug regimens. In general, the adherence is very low but comparable to previously published studies from other countries. This variability of adherence should be considered in clinical decision making together with the variability of therapeutic efficiency found in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24887334     DOI: 10.5414/CP202072

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  2 in total

Review 1.  A systematic review of factors affecting medication adherence among patients with osteoporosis.

Authors:  C T Yeam; S Chia; H C C Tan; Y H Kwan; W Fong; J J B Seng
Journal:  Osteoporos Int       Date:  2018-11-12       Impact factor: 4.507

2.  Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia.

Authors:  Olga Růžičková; Zdenko Killinger; Petr Kasalický; Lisa Hamilton; Roman Tyl; Soňa Tomková; Lama Kalouche-Khalil
Journal:  Adv Ther       Date:  2018-09-06       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.